Clinical trials: Psoriasis Patients
Plaque Type Psorisis, Non-pustular Palmoplantar Psoriasis
Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
This single-center interventional study was designed to evaluate the efficacy and safety of two CE-marked topical medical devices: PROXERA PSOMED 20 is being studied in participants with non-palmoplantar plaque psoriasis, while…
- Trial name
- PASI (NCT07545902)
- Testing
- PROXERA PSOMED 20 cream; PROXERA PSOMED 40 gel
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- ICIM International S.r.l.
Chronic Stable Plaque Psoriasis
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel
The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
- Trial name
- EGALITY (NCT01891864)
- Testing
- GP2015 Etanercept, Enbrel
- Where
- 74 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 531 people
- Sponsor
- Sandoz
Psoriasis
Prevalence of Sonographic Abnormalities of Joints and Entheses in Psoriasis Patients With or Without Musculoskeletal Complains
The objectives of this study are: to estimate the prevalence and severity of inflammatory (synovitis, tenosynovitis, enthesitis, dactylitis) and structural (erosions, osteophytes, enthesophytes, cortical irregularities )…
- Trial name
- EchoPso (NCT04074070)
- Testing
- Ultrasound examination
- Where
- France
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriasis (PsO), Moderate to Severe Psoriasis
Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration.
- Trial name
- PRO/PsO (NCT07370766)
- Where
- 7 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Chronicle Academy
Moderate to Severe Chronic Plaque Psoriasis
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
- Trial name
- NCT01758705
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Observational Study of Apremilast in Patients With Psoriasis in The Netherlands
This is a multicenter, prospective, non-interventional, observational single arm study. Two-hundred patients will be recruited in the Netherlands over a one year period.
- Trial name
- APRIL (NCT02652494)
- Where
- 12 sites in Netherlands
- Volunteers
- 154 people
- Sponsor
- Amgen
Psoriasis
CT 327 in the Treatment of Psoriasis Vulgaris
This study will look at how safe and effective, a novel agent, CT 327 cream is in treating patients with mild to moderate psoriasis vulgaris (PV).
- Trial name
- NCT00995969
- Testing
- CT 327
- Where
- 12 sites in United States, Switzerland and 1 more
- Volunteers
- 58 people
- Sponsor
- Creabilis SA
Arthritis, Psoriatic
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
The purpose of this study is to evaluate the efficacy (improvement of signs and symptoms) and safety of ustekinumab in patients with psoriatic arthritis.
- Trial name
- NCT01077362
- Testing
- ustekinumab 45 mg, ustekinumab 90 mg
- Where
- 80 sites in United States, Austria and 8 more
- Volunteers
- 312 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- PHOENIX1 (NCT00267969)
- Testing
- ustekinumab
- Where
- 42 sites in United States, Belgium and 1 more
- Volunteers
- 766 people
- Sponsor
- Centocor Research & Development, Inc.
Psoriasis
A Study of QY101 Ointment in Subjects With Plaque Psoriasis
The goal of this clinical trial is to evaluate the effectiveness of QY101 ointment in adult patients with plaque psoriasis (2-20% BSA).
- Trial name
- NCT06170840
- Where
- China
- Volunteers
- 160 people
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Psoriasis
Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity
Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with stable disease.
- Trial name
- NCT02602925
- Testing
- Dose decrease, Usual care
- Where
- 6 sites in Netherlands
- Volunteers
- 120 people
- Sponsor
- Radboud University Medical Center
Tuberculosis, Psoriasis
Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis
The purpose of this study is to determine the level of agreement between QuantiFeron -TB Gold test (QFT-G)and Tubeculin skin test (TST)for screening of latent tuberculosis in patients suffering from psoriasis.
- Trial name
- NCT01223976
- Testing
- Tuberculin skin test and Quantiferon -TB Gold test
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.
- Trial name
- IXORA-S (NCT02561806)
- Testing
- Ixekizumab, Ustekinumab
- Where
- 48 sites in Austria, Belgium and 11 more
- Volunteers
- 302 people
- Sponsor
- Eli Lilly and Company
Psoriasis Vulgaris
Hormonal Associations in Male Patients With Psoriasis Vulgaris
A cross sectional clinical study will be conducted on male patients with moderate and sever psoriasis vulgaris to: Identify the pattern of serum testosterone level and tissue androgen receptors.
- Trial name
- NCT05716152
- Testing
- Morning blood sample and skin punch biopsy of 4 mm diameter.
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Sohag University
Psoriasis, Atopic Dermatitis
Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
Psoriasis is a common inflammatory disease of the skin and joints with a prevalence of 1-3% in the caucasian population of Northern Europe and the US.
- Conditions
- Psoriasis, Atopic Dermatitis, Atherosclerosis
- Trial name
- NCT01356758
- Testing
- biological treatment
- Where
- Denmark
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Psoriasis
Therapeutic Education Program in Psoriasis
The primary objective of this research protocol is to assess the effect of a structured therapeutic education program on the quality of life of patients with moderate to severe psoriasis
- Trial name
- EDUPSO (NCT02310204)
- Testing
- multidisciplinary education program, standard psoriasis care alone
- Where
- 9 sites in France
- Volunteers
- 187 people
- Sponsor
- University Hospital, Toulouse
Psoriatic Arthritis
The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory diseases . Recent evidence suggest that psoriatic arthritis is also associated with an increased cardiovascular risk with accelerated…
- Trial name
- NCT01818804
- Testing
- n-3PUFA, olive oil
- Where
- 2 sites in Denmark
- Volunteers
- 145 people
- Sponsor
- Aalborg University Hospital
Plaque Psoriasis
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in…
- Trial name
- ONWARD2 (NCT06588738)
- Testing
- Envudeucitinib, Apremilast
- Where
- 124 sites in United States, Austria and 10 more
- Volunteers
- 862 people
- Sponsor
- Alumis Inc
Psoriasis
Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)
Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence of erythematous and itchy plaques. Psoriasis has a multifactorial pathogenesis, environmental and genetic factors contribute to its…
- Trial name
- NCT06792487
- Testing
- skin biopsy
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Plaque Psoriasis
To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis
The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with moderate to severe plaque psoriasis.
- Trial name
- NCT07008547
- Testing
- Netakimab
- Where
- China
- Volunteers
- 202 people
- Sponsor
- SPH-BIOCAD (HK) Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.